Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Inhibikase Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Inhibikase Therapeutics's earnings have been declining at an average annual rate of -33.7%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been declining at an average rate of 33.7% per year.
Anahtar bilgiler
-33.7%
Kazanç büyüme oranı
-2.6%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | -33.7% |
| Özkaynak getirisi | -360.7% |
| Net Marj | -23,102.2% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?
Jan 25
Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia
Aug 26Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M
Aug 12Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?
Aug 09Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation
Apr 06Inhibikase Therapeutics prices stock offering at $3
Jun 16Gelir ve Gider Dağılımı
Inhibikase Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -18 | 7 | 0 |
| 31 Mar 24 | 0 | -19 | 7 | 0 |
| 31 Dec 23 | 0 | -19 | 7 | 0 |
| 30 Sep 23 | 0 | -19 | 7 | 0 |
| 30 Jun 23 | 0 | -19 | 7 | 0 |
| 31 Mar 23 | 0 | -18 | 6 | 0 |
| 31 Dec 22 | 0 | -18 | 6 | 0 |
| 30 Sep 22 | 0 | -19 | 7 | 0 |
| 30 Jun 22 | 0 | -19 | 7 | 0 |
| 31 Mar 22 | 2 | -17 | 7 | 0 |
| 31 Dec 21 | 3 | -15 | 7 | 0 |
| 30 Sep 21 | 3 | -11 | 6 | 0 |
| 30 Jun 21 | 3 | -7 | 5 | 0 |
| 31 Mar 21 | 2 | -5 | 4 | 0 |
| 31 Dec 20 | 1 | -3 | 3 | 0 |
| 30 Sep 20 | 1 | -2 | 2 | 0 |
| 30 Jun 20 | 1 | -3 | 2 | 0 |
| 31 Mar 20 | 1 | -5 | 4 | 0 |
| 31 Dec 19 | 1 | -6 | 4 | 0 |
| 30 Sep 19 | 2 | -7 | 5 | 0 |
| 31 Mar 19 | 4 | -4 | 3 | 0 |
| 31 Dec 18 | 4 | -2 | 3 | 0 |
| 30 Sep 18 | 3 | -1 | 2 | 0 |
| 31 Mar 18 | 3 | 0 | 1 | 0 |
| 31 Dec 17 | 2 | 0 | 1 | 0 |
| 31 Dec 16 | 1 | -1 | 1 | 0 |
Kaliteli Kazançlar: IKT is currently unprofitable.
Büyüyen Kar Marjı: IKT is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: IKT is unprofitable, and losses have increased over the past 5 years at a rate of 33.7% per year.
Büyüme Hızlandırma: Unable to compare IKT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: IKT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Özkaynak Getirisi
Yüksek ROE: IKT has a negative Return on Equity (-360.68%), as it is currently unprofitable.